X0306 4 2019-11-12 0 0001563577 Galera Therapeutics, Inc. GRTX 0001297709 Novartis Bioventures Ltd C/O NOVARTIS VENTURE FUND FORUM 1 - 1.32, LICHTSTRASSE 35, CH-4056 BASEL V8 CH-4056 SWITZERLAND 0 0 1 0 0001114448 NOVARTIS AG LICHTSTRASSE 35, CH-4056 BASEL V8 CH-4056 SWITZERLAND 0 0 1 0 Common Stock 2019-11-12 4 C 0 3293067 A 3293067 I See footnote Common Stock 2019-11-12 4 P 0 250000 12.00 A 3543067 I See footnote Series A Preferred Stock 2019-11-12 4 C 0 9000000 D Common Stock 1779864 0 I See footnote Series B Preferred Stock 2019-11-12 4 C 0 7200000 D Common Stock 1423891 0 I See footnote Series C Preferred Stock 2019-11-12 4 C 0 451609 D Common Stock 89311 0 I See footnote Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities. Novartis Bioventures Ltd., By: /s/ Bart Dzikowski, Name: Bart Dzikowski, Title: Secretary of the Board, By: /s/ Stephan Sandmeier, Name: Stephan Sandmeier, Title: Authorized Signatory 2019-11-12 Novartis AG, By: /s/ Bart Dzikowski, Name: Bart Dzikowski, Title: Attorney-in-Fact, By: /s/ Stephan Sandmeier, Name: Stephan Sandmeier, Title: Attorney-in-Fact 2019-11-12